AntiCancer, Inc.

SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc. announced it has just received US Patent 11,871,731 that describes a method to increase the rate of establishment of patient tumors in mice to close to 100%. Previously the establishment rates were much lower, in many cases only 10-20% in laboratories around the world. “The new method allows, for the first time, large scale and commercial success of establishing mouse models for each cancer patient to individualize and optimize their cancer therapy, as well as banking their tumors after establishment for future therapy,” said Chihiro Hozumi, co-inventor of the patent and General Manager of AntiCancer’s Japanese subsidiary, AntiCancer Japan. “The new method is especially important as almost all cancer patients can now have their own individualized clinically-concordant PDOX mouse model,” said AntiCancer Senior Mouse-Model Scientist Jose Reynoso. “The new method facilitates the discovery of effective cancer drugs, since many more mouse models of cancer with patient tumors will be available for testing of novel cancer drugs,” said AntiCancer Senior Scientist Qinghong Han. AntiCancer Inc. of San Diego was established in 1984 and is celebrating its 40th anniversary. AntiCancer is a world leader in developing individualized cancer therapy, including contract research, using its proprietary PDOX mouse model which it has developed since 1987, and most closely represents the cancer patient. View source version on businesswire.com: Contacts Qinghong Han, MD all@anticancer.com Source: AntiCancer Inc. View this news release online at:

SAN DIEGO--(BUSINESS WIRE)-- AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate prediction of chemotherapy outcome for the patient,” said Dr. Han. “AntiCancer’s technique of patient-tumor establishment in mice is close to 100%, making the PDOX model available potentially to all patients,” technique-inventor and AntiCancer-Japan General Manager Chihiro Hozumi said. AntiCancer has published 165 scientific papers on its PDOX model since 1991. The latest paper on clinical concordance of the PDOX model is published in the October 2023 issue of Anticancer Research. AntiCancer Inc., San Diego, is a world leader in mouse models of cancer; small-animal imaging; methionine-restriction treatment of cancer; bacterial therapy of cancer, adult stem cells for regenerative medicine, in vitro assays of cancer therapy, a pioneer in fluorescence-guided surgery, and more, demonstrated in 1200 scientific publications and almost 200 patents. AntiCancer Inc. was founded in 1984. View source version on businesswire.com: Contacts Qinghong Han, MD all@anticancer.com Source: AntiCancer Inc. View this news release online at:

High risk of human papillomavirus infection to lead to cervical cancer impels demand for cervical cancer diagnostic tests for prevention of cervical cancer North America to continue to remain key market with easy access to screening solutions and affordability for expensive diagnostic procedures ALBANY, N.Y., June 29, 2022 /PRNewswire/ -- The cervical cancer diagnostic tests market is projected to expand at a CAGR of 4.6% for the forecast period from 2022 to 2031. Increasing prevalence of cervical cancer in women which is related to a number of causative factors propels the cervical cancer diagnostic tests market. According to the World Health Organization, cervical cancer is the second most commonly prevalent cancer and the third-largest cause of death in women with 530,000 new cases each year. For example, in 2018, approximately 570, 000 women were diagnosed with cervical cancer globally and nearly 310, 000 deaths were reported related to the disease. High incidence of human papillomavirus infection in women population and long-term use of oral contraceptives that are related to cervical cancer underscores demand for cervical cancer diagnostic tests. Role of large pharmaceutical companies toward discovering improved treatment for cervical cancer is benefitting the cervical cancer diagnostic tests market. The introduction of technologically advanced computer-assisted cervical cancer screening tests to reduce shortcomings of predecessor tests and for improved accuracy contributes to the growth of cervical cancer diagnostic tests market. Request Brochure of Cervical Cancer Diagnostic Tests Market Research Report – Cervical Cancer Diagnostic Tests Market – Key Findings of the Report Increasing awareness for early stage diagnosis of cancer coupled with rising demand for advanced screening techniques are some key factors for ongoing trends of cervical cancer diagnostic tests market Pap smear diagnostic test held the leading share of cervical cancer diagnostic tests market in 2021, and is anticipated to continue to remain at the fore during the forecast period. Increasing number of patients with high-risk human papillomavirus infection and increasing number of teenage sex are some key factors fuelling the growth of Pap smear diagnostic test segment. Hospitals end-user segment accounted for key share of cervical cancer diagnostic tests market in 2021. Factors such as availability of multiple service options and tie-ups with healthcare companies for advanced medical devices makes hospitals preferred among patients. Nonetheless, specialty clinics segment is projected to expand at a significant growth rate especially in developed countries to offload burden on hospitals. North America held the leading share of cervical cancer diagnostic tests market in 2021. Large baby boomer population that can afford expensive diagnostic tests and presence of some large diagnostic kits and device providers that enables easy access to screening solutions are creating opportunities in the cervical cancer diagnostic tests market of the region. Increasing demand for preventive diagnostics in developing countries to account for significant growth of cervical cancer diagnostic tests market in Asia Pacific in the upcoming years Diversification of product portfolio is a key growth strategy of companies in the cervical cancer diagnostic tests market. The launch of a human papillomavirus self-sampling testing kit from F. Hoffmann-La Roche Ltd for regions that accept CE mark is a significant cervical cancer diagnostic tests market development Request for Analysis of COVID-19 Impact on Cervical Cancer Diagnostic Tests Market – Cervical Cancer Diagnostic Tests Market – Growth Drivers Statistics of cervical cancer as the second most commonly prevalent and third-largest cause of death in women propels the cervical cancer diagnostic tests market Increasing demand for advanced screening techniques for early stage diagnosis of cancer underscores growth of cervical cancer diagnostic tests market Get Exclusive PDF Sample Copy of Cervical Cancer Diagnostic Tests Market Report – Cervical Cancer Diagnostic Tests Market – Key Players Some of the key players operating in the cervical cancer diagnostic tests market are; F. Hoffmann-La Roche Ltd. Quest Diagnostics Incorporated Hologic Inc. Femasys Inc. Cooper Companies Inc. Abbott QIAGEN DYSIS Medical Inc. Guided Therapeutics Inc. BD Make an Enquiry Before Buying – The cervical cancer diagnostic tests market is segmented as follows; Cervical Cancer Diagnostic Tests Market, by diagnostic test Pap Smear Test HPV Test Colposcopy Biopsy & Endocervical Curettage Other diagnostic tests Cervical Cancer Diagnostic Tests Market, by End-user Hospitals Specialty Clinics Others Cervical Cancer Diagnostic Tests Market, by Region North America Europe Asia Pacific Latin America Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Research Reports by Transparency Market Research: Cancer Immunotherapy Market: Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. HER2 Breast Cancer Test Market: Rise in prevalence of breast cancer across the globe is projected to drive the global HER2 breast cancer test market during the forecast period. Breast cancer in women is a primary health burden globally. Hyperthermia Cancer Treatment Market: The hyperthermia cancer treatment market is predicted to reach US$ 266 Mn by the end of 2030. The deep tissue thermal therapy is gaining prominence in the cancer treatment space, especially among patients with breast cancer. Cancer Diagnostics Market: Increasing trend for preventive diagnosis due to escalating prevalence continues, early diagnosis enables better clinical and economical outcomes for patients are projected to drive the global cancer diagnostics market during the forecast period. Breast Cancer Diagnostics Market: High prevalence and increase in incidence rate of breast cancer across the globe and technological advancements in diagnostic techniques are anticipated to fuel the growth of the global breast cancer diagnostics market. Prostate Cancer Therapeutics Market: The prostate cancer therapeutics market was valued at ~US$ 10 Bn in 2019, and is projected to arrive at a value tantamount to ~US$ 19.6 Bn by 2027, expanding at a CAGR of ~8% during the period of 2019-2027. Head and Neck Cancer Market: The global head and neck cancer market is driven by increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, surge in research and development activity, increase in product approvals, and rise in government initiatives. Anticancer Drugs Market: The increasing number of deaths caused due to cancer is a prime factor augmenting the growth of the global anticancer drugs market. Cancer is a gathering of sicknesses related with strange cell development with the possibility to torment or spread to different pieces of the body. About Transparency Market Research Transparency Market Research is a global market research company providing business custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research